ES2182220T3 - Derivados de acido 3,7-ditiaprostanoico. - Google Patents

Derivados de acido 3,7-ditiaprostanoico.

Info

Publication number
ES2182220T3
ES2182220T3 ES98300513T ES98300513T ES2182220T3 ES 2182220 T3 ES2182220 T3 ES 2182220T3 ES 98300513 T ES98300513 T ES 98300513T ES 98300513 T ES98300513 T ES 98300513T ES 2182220 T3 ES2182220 T3 ES 2182220T3
Authority
ES
Spain
Prior art keywords
alquenilo
rent
group
ditiaprostanoic
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98300513T
Other languages
English (en)
Spanish (es)
Inventor
Toru Maruyama
Shuichi Ohuchida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2182220T3 publication Critical patent/ES2182220T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Microscoopes, Condenser (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
ES98300513T 1997-01-27 1998-01-26 Derivados de acido 3,7-ditiaprostanoico. Expired - Lifetime ES2182220T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2719897 1997-01-27

Publications (1)

Publication Number Publication Date
ES2182220T3 true ES2182220T3 (es) 2003-03-01

Family

ID=12214403

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98300513T Expired - Lifetime ES2182220T3 (es) 1997-01-27 1998-01-26 Derivados de acido 3,7-ditiaprostanoico.

Country Status (8)

Country Link
US (1) US5892099A (https=)
EP (1) EP0855389B1 (https=)
JP (1) JPH10265454A (https=)
AT (1) ATE218543T1 (https=)
DE (1) DE69805665T2 (https=)
DK (1) DK0855389T3 (https=)
ES (1) ES2182220T3 (https=)
PT (1) PT855389E (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043275A (en) * 1998-04-16 2000-03-28 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
EP1121133A1 (en) * 1998-10-15 2001-08-08 Merck & Co., Inc. Methods for stimulating bone formation
US6414006B1 (en) 1998-10-15 2002-07-02 Merck Frosst Canada & Co. Methods for inhibiting bone resorption
JP4834224B2 (ja) 1999-03-05 2011-12-14 デューク ユニバーシティ Ｃ１６不飽和ｆｐ−選択的プロスタグランジン類縁体
CA2332375A1 (en) * 1999-03-16 2000-09-21 Masafumi Isogaya Cervical ripening agent and cervical ripening method
US6894175B1 (en) * 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
JP4618548B2 (ja) * 1999-11-24 2011-01-26 小野薬品工業株式会社 骨量低下疾患治療剤
BR0015781A (pt) * 1999-11-24 2002-12-31 Ono Pharmaceutical Co Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
TWI247606B (en) * 1999-11-24 2006-01-21 Ono Pharmaceutical Co Treating agent for osteopenic diseases
IL141120A0 (en) * 2000-01-31 2002-02-10 Pfizer Prod Inc Use of prostaglandin (pge2) receptor 4 (epa) selective agonists for the treatment of acute and chronic renal failure
US20020013294A1 (en) * 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
AU2001290250A1 (en) * 2000-09-21 2002-04-02 Ono Pharmaceutical Co. Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
GB0103269D0 (en) * 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
US6410591B1 (en) * 2001-05-08 2002-06-25 Allergan Sales, Inc. 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
US20030027853A1 (en) 2001-06-14 2003-02-06 Allergan Sales, Inc. 3, 7or3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
US7872045B2 (en) 2001-06-14 2011-01-18 Allergan, Inc. Combination therapy for glaucoma treatment
US20050222094A1 (en) * 2001-06-14 2005-10-06 Burk Robert M Treatment of inflammatory bowel disease
EP1490055A1 (en) * 2002-03-18 2004-12-29 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
AU2003224244A1 (en) * 2002-03-27 2003-10-13 Rosanto Pharmaceuticals Ltd Improvements in pharmaceutical compositions
AU2003233729B2 (en) 2002-06-06 2007-10-04 Merck Frosst Canada Ltd 1,5-distributed pyrrolid-2-one derivatives for use as EP4 receptor agonists in the treatment of eye diseases such as glaucoma
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
WO2004073589A2 (en) * 2003-02-24 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep4 (prostaglandin e2 ep4)
EP1742662A2 (en) * 2004-05-03 2007-01-17 Astellas Pharma Inc. Combination of prostaglandin e2 receptor antagonists and renin-angiotensin system inhibitors for treating renal diseases
WO2006016695A1 (ja) * 2004-08-10 2006-02-16 Ono Pharmaceutical Co., Ltd. Ｅｐ４アゴニストを含有してなる高カリウム血症の予防および／または治療剤
WO2006047466A2 (en) 2004-10-21 2006-05-04 Duke University Ophthamological drugs
UY30121A1 (es) 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
US9394520B2 (en) 2006-12-08 2016-07-19 University Of Rochester Expansion of hematopoietic stem cells
US20080167377A1 (en) 2006-12-15 2008-07-10 Alessandra Gaiba Novel compounds
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
CA2738045C (en) 2010-05-28 2019-02-19 Simon Fraser University Conjugate compounds, methods of making same, and uses thereof
US9650414B1 (en) 2014-05-30 2017-05-16 Simon Fraser University Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
CN107849072B (zh) 2015-06-12 2020-12-15 西蒙弗雷泽大学 酰胺连接的ep4激动剂-二膦酸盐化合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57108065A (en) * 1980-12-26 1982-07-05 Teijin Ltd 7-thiaprostaglandin e1 derivative, its preparation, and blood platelet coagulation inhibiting agent containing said derivative as active component
EP0051284B1 (en) * 1980-10-31 1985-01-09 Teijin Limited Novel thiaprostaglandin e1 derivatives, process for production thereof, and pharmaceuticals containing these compounds
JPS58110562A (ja) * 1981-12-25 1983-07-01 Teijin Ltd 新規な７−チアプロスタグランジンｅ↓１誘導体類、それらの製造方法及びそれらを活性成分とする薬剤
JPS58148857A (ja) * 1982-02-26 1983-09-05 Teijin Ltd 新規な１３，１４−ジヒドロ−７−チアプロスタグランジンｅ↓１類およびその製造方法

Also Published As

Publication number Publication date
DE69805665T2 (de) 2002-11-21
EP0855389A3 (en) 1999-06-16
DE69805665D1 (de) 2002-07-11
DK0855389T3 (da) 2002-10-14
PT855389E (pt) 2002-10-31
ATE218543T1 (de) 2002-06-15
EP0855389B1 (en) 2002-06-05
JPH10265454A (ja) 1998-10-06
US5892099A (en) 1999-04-06
EP0855389A2 (en) 1998-07-29

Similar Documents

Publication Publication Date Title
ES2182220T3 (es) Derivados de acido 3,7-ditiaprostanoico.
PA8463501A1 (es) Derivados de acido hidroxamico como inhibidores de metaloproteasas de matriz (mmp)
ES2178808T3 (es) Derivados omega-cicloalquil-prostaglandina e2.
ES2152444T3 (es) Derivados de acido benzazepin-, benzoxazepin- y benzotiazepin-n-acetico, asi como procedimiento para su preparacion y medicamentos que contienen a estos compuestos.
BR9811585A (pt) Agonistas de vasopressinas tricìclicas
ES2168357T3 (es) Agonistas del receptor ep2 como agentes para disminuir la presion intraocular.
ES2096329T3 (es) Procedimiento para la preparacion de derivados del taxano.
PE25198A1 (es) Nuevos taxoides, su preparacion y las composiciones farmaceuticas que las contienen
ES2045106T3 (es) Composiciones de blanqueo.
EP0675878A1 (en) NEW VITAMIN D ANALOGS
ES2127912T3 (es) Benzoderivados condensados.
PT89346A (pt) Processo para a preparacao de novas lactamas triciclicas contendo grupos sulfridilo e de composicoes farmaceuticas que as contem
BR9713178A (pt) Inbidores espirocìclicos da metaloprotease.
ATE292460T1 (de) Zusammenstellungen die aktive stilbenoidverbindungen enthalten zur senkung des triglyceridspiegels
UY26199A1 (es) Nuevos derivados de benceno, un procedimiento para su preparación y las composiciones farmacéuticas que los contienen
TR200000673T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler.
ES2117281T3 (es) Nuevos analogos de la vitamina d.
DE69712042D1 (de) Thiazolylbenzofuranderivate und pharmazeutische zusammensetzungen die sie enthalten
BR9713261A (pt) Tricìclicos substituìdos
BR0007229A (pt) Aminoazaciclos heterocìclicos substituìdos úteis como agentes de sistema nervoso central
RU93005334A (ru) Производные стероидов для лечения гипертрофии предстательной железы, способ их получения, использование, фармкомпозиция
BR0215801A (pt) Derivados de 3,6-dissubstituìdos azabiciclo [3.1.0] hexano úteis como antagonistas de receptores muscarìnicos
ES2114619T3 (es) Nuevos analogos de la vitamina d.
ES2032066T3 (es) Procedimiento para la coagulacion de barnices y otros recubrimientos organicos.
EP1306093A4 (en) PROMOTERS OF THE NERVOUS REGENERATION CONTAINING A SEMAPHORINE INHIBITOR AS THE ACTIVE COMPONENT